As rumors swirl, Actelion chair says 'no sale'

Actelion reiterated it wants to stay independent despite intense takeover speculation, its top managers told the Financial Times. "The board and management are confident about the future prospects of the company as an independent entity and we're not considering a sale," Chairman Robert Cawthorn told the paper. Report

Suggested Articles

The FDA is bracing for drug and medical supply shortages in the U.S. as the COVID-19 outbreak from China continues to spread globally.

Astellas and Seattle Genetics are out with Padcev-Keytruda combo data that may be good enough to snag an expedited regulatory review, analysts say.

Distributors had offered billions of dollars to wrap up opioid litigation, but that effort has suffered a major setback, WSJ reports.